Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

FDA approves Lilly-backed Bluetooth insulin device

Clears Companion Medical’s Bluetooth-enabled pen and smartphone app

Digital pharmaUS regulators have cleared a Bluetooth-enabled insulin pen and associated smartphone app from Companion Medical.

The San Diego-based medical device firm last year received funding from Lilly, with the pharma company gaining a seat on Companion's board. The FDA approved Companion's InPen system for use with Lilly's Humalog or Novo Nordisk's Novolog rapid acting insulins and also passed its InPen app for Apple iOS.

The company plans to release an Android version later this year and has also filed for a CE Mark (kitemark) in Europe.

Sean Saint, Companion Medical's chief executive officer, said: "FDA clearance of the InPen and mobile app represents a significant advancement in diabetes care.

"The product combines the benefits of sophisticated insulin pumps with the simplicity and affordability of pens and syringes, providing patients, physicians, and caregivers increased confidence that diabetes is being managed optimally."

23rd August 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics